New Data from the Interim Analysis of REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in a Subgroup of High-Risk Patients with Fibrosis Due to NASH

    NEXT STORY
    Ziopharm Oncology Appoints Mary Thistle to Board of Directors
    PREV STORY
    Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Alimera Sciences Data Available for the 11th Annual Congress on Controversies in Ophthalmology: Europe Virtual Conference

    author_avatar
    NASDAQ Market News

    Interim Results from Biodesix® Study Indicate That VeriStrat Testing Impacts Treatment Decisions Across All Stages of Non-Small Cell Lung Cancer

    BOULDER, Colo., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Interim analysis of a new study ...

    author_avatar
    NASDAQ Market News

    Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC

    MADISON, Wis., March 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), ...

    author_avatar
    NASDAQ Market News